Pancreatic Cancer Research

ResearcherPhilipps University of MarburgActive in the last 2 years

Duncan Ian Jodrell

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9360-1670; OpenAlex author ID A5071360446. Sources: ClinicalTrials.gov.

Their work

Papers
24 (first author 1, last author 9)
Trials
2 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
79
Papers, trials and grants by year

2010: 1 trial · 2011: none · 2012: 6 papers · 2013: 3 papers · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 1 trial · 2018: 2 papers · 2019: 2 papers · 2020: 2 papers · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: none · 2025: 1 paper

Papers 24

  1. Transcription factor switching drives subtype-specific pancreatic cancer. Co-author DOI 10.1038/s41588-025-02389-7↗
  2. Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-023-02170-9↗
  3. Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinom… Last author DOI 10.1136/jitc-2022-006457↗
  4. Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multimodal Imaging. Last author DOI 10.1021/acs.analchem.1c04579↗
  5. Size-tuneable and immunocompatible polymer nanocarriers for drug delivery in pancreatic cancer. Co-author DOI 10.1039/d2nr00864e↗
  6. T Cell-Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Canc… Co-author DOI 10.1158/1535-7163.mct-20-0620↗
  7. Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. Last author DOI 10.1038/s41416-020-0846-2↗
  8. Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models. Last author DOI 10.1038/s41416-020-1016-2↗
  9. Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites. Co-author DOI 10.1016/j.ebiom.2019.01.037↗
  10. Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-1398↗
  11. A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1038/bjc.2017.495↗
  12. The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression. Last author DOI 10.1158/1535-7163.mct-18-0010↗
  13. mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-16-0810↗
  14. GEMMs as preclinical models for testing pancreatic cancer therapies. Co-author DOI 10.1242/dmm.021055↗
  15. Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo. Co-author DOI 10.1038/bjc.2014.288↗
  16. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Co-author DOI 10.1073/pnas.1320318110↗
  17. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2012-302529↗
  18. Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer. Last author DOI 10.1371/journal.pone.0067330↗
  19. A novel Phase I/IIa design for early phase oncology studies and its application in the evaluation of MK-0752 in pancreatic cancer. Last author DOI 10.1002/sim.5331↗
  20. Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials. Co-author DOI 10.1016/j.pan.2011.12.009↗
  21. Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells. Last author DOI 10.1038/bjc.2012.450↗
  22. Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. Co-author DOI 10.1084/jem.20111923↗
  23. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Co-author DOI 10.1158/2159-8290.cd-11-0242↗
  24. Progress in pancreatic cancer: moving beyond gemcitabine? First author DOI 10.1586/era.12.78↗

Trials 2

  1. To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Co… Study chair NCT03277209↗
  2. MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery Principal investigator NCT01098344↗

Closest collaborators

The 25 strongest of 79 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Frances M. Richards · 10 shared papers, 2012–2023 · strength 0.86
  2. Rebecca J. Brais · 5 shared papers, 2012–2025 · strength 0.52
  3. David Arthur Tuveson · 10 shared papers, 2012–2020 · strength 0.43
  4. Aarthi Gopinathan · 6 shared papers, 2012–2022 · strength 0.39
  5. Bristi Basu · 4 shared papers, 2012–2023 · strength 0.37
  6. Tashinga E. Bapiro · 8 shared papers, 2012–2021 · strength 0.37
  7. Albrecht Neeße · 7 shared papers, 2012–2020 · strength 0.31
  8. Yann Wallez · 3 shared papers, 2018–2022 · strength 0.30
  9. Charles R. Dunlop · 3 shared papers, 2018–2022 · strength 0.30
  10. Natalie Cook · 8 shared papers, 2012–2018 · strength 0.29
  11. Pippa G. Corrie · 3 shared papers, 2012–2023 · strength 0.27
  12. Jennifer P. Morton · 3 shared papers, 2015–2023 · strength 0.26
  13. Brajesh Pratap Kaistha · 2 shared papers, 2022–2023 · strength 0.25
  14. Alimu Dayimu · 2 shared papers, 2020–2023 · strength 0.24
  15. Juan W. Valle · 2 shared papers, 2020–2023 · strength 0.24
  16. Owen James Sansom · 3 shared papers, 2015–2022 · strength 0.23
  17. Elizabeta Popa · 1 shared trial, 2017 · strength 0.22
  18. Kristopher K. Frese · 5 shared papers, 2012–2019 · strength 0.20
  19. Hideo Baba · 1 shared paper, 2025 · strength 0.17
  20. Phyllis F. Cheung · 1 shared paper, 2025 · strength 0.17
  21. Barbara T. Grünwald · 1 shared paper, 2025 · strength 0.17
  22. Niklas Krebs · 1 shared paper, 2025 · strength 0.17
  23. Shalini V. Rao · 1 shared paper, 2025 · strength 0.17
  24. Jason S. Carroll · 1 shared paper, 2025 · strength 0.17
  25. Jens Thomas Siveke · 1 shared paper, 2025 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.